Engineers Gate Manager LP Jounce Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $111,185 - $157,989	-18,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $131,535 - $178,340	18,500 New	18,500 $154,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $123,480 - $213,885	-24,500 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $161,210 - $261,170	24,500 New	24,500 $167,000
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $96,239 - $198,341	-14,300 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $91,091 - $147,719	14,300 New	14,300 $100,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $50,925 - $152,250	-17,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $49,175 - $161,175	17,500 New	17,500 $153,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.